Berkley Gryder

Title: Berkley Gryder: Innovator in Prostate Cancer Treatment

Introduction

Berkley Gryder is a notable inventor based in Atlanta, GA (US). He has made significant contributions to the field of cancer treatment, particularly focusing on prostate tumors. His innovative work has led to the development of a patent that addresses critical medical challenges.

Latest Patents

Gryder holds a patent for "Histone deacetylase (HDAC) inhibitors targeting prostate tumors and methods of making and using thereof." This patent describes compounds of Formula (I), which include an aryl group and a Zinc Binding Group, among other defined substituents. The compounds can be administered as pharmaceutically acceptable salts, prodrugs, or solvates. They are designed to treat and/or prevent hyperproliferative disorders, including hormone-sensitive and hormone-refractory prostate cancers. The formulation of these compounds can be combined with a pharmaceutically acceptable carrier and optional excipients for enteral or parenteral administration.

Career Highlights

Berkley Gryder is affiliated with the Georgia Tech Research Corporation, where he continues to advance his research and development efforts. His work is characterized by a commitment to improving therapeutic options for patients suffering from prostate cancer.

Collaborations

Gryder collaborates with Adegboyega K Oyelere, a talented woman in the field, contributing to the innovative research environment at Georgia Tech.

Conclusion

Berkley Gryder's contributions to the field of cancer treatment through his patent on HDAC inhibitors exemplify the impact of innovative research in medicine. His work continues to pave the way for advancements in the treatment of prostate cancer.